DES versus Tamoxifen in Advanced Breast Cancer

L. V.A.M. Beex; G. F.F.M. Pieters; A. G.H. Smals; A. J.M. Koenders; Th J. Benraad; P. W.C. Kloppenborg; Christian Jacquot; Rosalinda Graterol; Jean Bariety; Loïc Capron; Jean Noël Fiessinger; Ian Tannock; Norman Boyd; Roy Clark; Merrill I. Feldman; James N. Ingle

doi:10.1056/NEJM198104233041714

DES versus Tamoxifen in Advanced Breast Cancer

L. V.A.M. Beex, G. F.F.M. Pieters, A. G.H. Smals, A. J.M. Koenders, Th J. Benraad, P. W.C. Kloppenborg, Christian Jacquot, Rosalinda Graterol, Jean Bariety, Loïc Capron, Jean Noël Fiessinger, Ian Tannock, Norman Boyd, Roy Clark, Merrill I. Feldman, James N. Ingle

Medical Oncology

Research output: Contribution to journal › Letter › peer-review

10 Scopus citations

Abstract

To the Editor: In their article in the January 1 issue, Ingle et al.¹ stated that in four of 11 patients who had tumor regression and subsequent reactivation during treatment with diethylstilbestrol (DES), withdrawal reactions were observed after discontinuation of this drug. Patients in whom DES failed and patients first treated with tamoxifen were not entered into a withdrawal phase but were subsequently treated with tamoxifen or DES. In the discussion, the authors speculate that some of the tumor regressions observed during subsequent DES treatment were in fact withdrawal responses to discontinuation of tamoxifen. In a randomized trial we compared.

Original language	English (US)
Pages (from-to)	1041-1043
Number of pages	3
Journal	New England Journal of Medicine
Volume	304
Issue number	17
DOIs	https://doi.org/10.1056/NEJM198104233041714
State	Published - Apr 23 1981

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJM198104233041714

Cite this

Beex, L. V. A. M., Pieters, G. F. F. M., Smals, A. G. H., Koenders, A. J. M., Benraad, T. J., Kloppenborg, P. W. C., Jacquot, C., Graterol, R., Bariety, J., Capron, L., Fiessinger, J. N., Tannock, I., Boyd, N., Clark, R., Feldman, M. I., & Ingle, J. N. (1981). DES versus Tamoxifen in Advanced Breast Cancer. New England Journal of Medicine, 304(17), 1041-1043. https://doi.org/10.1056/NEJM198104233041714

@article{aa3fff4586684658bea1da23fb636531,

title = "DES versus Tamoxifen in Advanced Breast Cancer",

abstract = "To the Editor: In their article in the January 1 issue, Ingle et al.1 stated that in four of 11 patients who had tumor regression and subsequent reactivation during treatment with diethylstilbestrol (DES), withdrawal reactions were observed after discontinuation of this drug. Patients in whom DES failed and patients first treated with tamoxifen were not entered into a withdrawal phase but were subsequently treated with tamoxifen or DES. In the discussion, the authors speculate that some of the tumor regressions observed during subsequent DES treatment were in fact withdrawal responses to discontinuation of tamoxifen. In a randomized trial we compared.",

author = "Beex, {L. V.A.M.} and Pieters, {G. F.F.M.} and Smals, {A. G.H.} and Koenders, {A. J.M.} and Benraad, {Th J.} and Kloppenborg, {P. W.C.} and Christian Jacquot and Rosalinda Graterol and Jean Bariety and Lo{\"i}c Capron and Fiessinger, {Jean No{\"e}l} and Ian Tannock and Norman Boyd and Roy Clark and Feldman, {Merrill I.} and Ingle, {James N.}",

year = "1981",

month = apr,

day = "23",

doi = "10.1056/NEJM198104233041714",

language = "English (US)",

volume = "304",

pages = "1041--1043",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "17",

}

TY - JOUR

T1 - DES versus Tamoxifen in Advanced Breast Cancer

AU - Beex, L. V.A.M.

AU - Pieters, G. F.F.M.

AU - Smals, A. G.H.

AU - Koenders, A. J.M.

AU - Benraad, Th J.

AU - Kloppenborg, P. W.C.

AU - Jacquot, Christian

AU - Graterol, Rosalinda

AU - Bariety, Jean

AU - Capron, Loïc

AU - Fiessinger, Jean Noël

AU - Tannock, Ian

AU - Boyd, Norman

AU - Clark, Roy

AU - Feldman, Merrill I.

AU - Ingle, James N.

PY - 1981/4/23

Y1 - 1981/4/23

N2 - To the Editor: In their article in the January 1 issue, Ingle et al.1 stated that in four of 11 patients who had tumor regression and subsequent reactivation during treatment with diethylstilbestrol (DES), withdrawal reactions were observed after discontinuation of this drug. Patients in whom DES failed and patients first treated with tamoxifen were not entered into a withdrawal phase but were subsequently treated with tamoxifen or DES. In the discussion, the authors speculate that some of the tumor regressions observed during subsequent DES treatment were in fact withdrawal responses to discontinuation of tamoxifen. In a randomized trial we compared.

AB - To the Editor: In their article in the January 1 issue, Ingle et al.1 stated that in four of 11 patients who had tumor regression and subsequent reactivation during treatment with diethylstilbestrol (DES), withdrawal reactions were observed after discontinuation of this drug. Patients in whom DES failed and patients first treated with tamoxifen were not entered into a withdrawal phase but were subsequently treated with tamoxifen or DES. In the discussion, the authors speculate that some of the tumor regressions observed during subsequent DES treatment were in fact withdrawal responses to discontinuation of tamoxifen. In a randomized trial we compared.

UR - http://www.scopus.com/inward/record.url?scp=0019435772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019435772&partnerID=8YFLogxK

U2 - 10.1056/NEJM198104233041714

DO - 10.1056/NEJM198104233041714

M3 - Letter

C2 - 7010171

AN - SCOPUS:0019435772

SN - 0028-4793

VL - 304

SP - 1041

EP - 1043

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 17

ER -

DES versus Tamoxifen in Advanced Breast Cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this